Status of neoadjuvant therapy for resectable pancreatic cancer

Neoadjuvant treatment in patients with pancreatic cancer has increased the efficiency of surgery and improved patients' response to radiotherapy. It has also been shown to expose previously occult metastatic disease and reduce the incidence of microscopically positive margins and leaks from the pancreatic-enteric anastomoses. This article focuses on the effects of the trials and studies conducted on neoadjuvant therapy and also on the hindrances and limitations that must be overcome for this therapy to gain widespread traction.